MedTrace Logo

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

NCT05612191 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-11-28

No results posted yet for this study

Summary

Catequentinib (AL3818, Anlotinib) has been developed in a variety of clinical studies as single agents or in combination with others. This trial is designed to offer patients who completed an Advenchen sponsored AL3818 related study without progression the opportunity to continue to receive this investigational product in this Post-Trial Access study (a compassionate use trial), if the Investigator believes the patients can benefit from such a treatment and the patients have signed the Informed Consent Form.

Conditions

  • Sarcoma,Soft Tissue
  • Gynecologic Cancer

Interventions

DRUG

AL3818

It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.

Sponsors & Collaborators

  • Advenchen Laboratories, LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612191 on ClinicalTrials.gov